Uppsala, Sweden, Oct. 24, 2016 (GLOBE NEWSWIRE) -- Oasmia acquires the project and strengthens its oncology project portfolio.
Karo Pharma receives 3,080,000 newly issued shares as a down payment corresponding to a value of MSEK 25. Additionally, Oasmia will
pay Karo Pharma 20% of all future revenues generated by the project for Oasmia.
Oasmia will continue the development process and will be responsible for all project expenses.
"This is a solid industrial solution where the companies can focus within their respective areas. Oasmia, which has several
cancer projects in both early and late developmental phase, strengthens its already unique product portfolio. The collaboration is
based on a separation of focus that will work well and I am personally committed to making this a successful collaboration for both
companies" says Anders Lonner, Executive Chairman in Karo Pharma.
"This is a very exciting acquisition for Oasmia as the project will complement the company's current product portfolio with
novel innovative candidates within our focus area. A prerequisite in this transaction from our side has been to get access to
Anders Lonners unique track record in developing companies and his international business experience. Since we are looking forward
to several registrations of new pharmaceutical products, his expertise will be very valuable. Anders Lonner is proposed to be part
of Oasmia's Board of Directors and will also be proposed as chairman at an extraordinary shareholders meeting." says Julian
Aleksov, largest shareholder in Oasmia Pharmaceutical.
Stockholm Corporate Finance has been advising Oasmia in this transaction.
About Oasmia Pharmaceutical AB
Oasmia Pharmaceutical AB develops, manufactures, markets and sells new generations of drugs in the field of human and veterinary
oncology. The company's product development aims to create and manufacture novel nanoparticle formulations and drug-delivery
systems based on well-established cytostatics, which, in comparison with current alternatives, show, improved properties, reduced
side-effects, and expanded applications. The company's product development is based on its proprietary in-house research and
company patents. Oasmia is listed on NASDAQ Capital Markets (OASM.US), Frankfurt Stock Exchange (OMAX.GR, ISIN SE0000722365) and
NASDAQ Stockholm (OASM.ST).
About Karo Pharma AB
Karo Pharma is a Health Care company, which develops and markets products for pharmacies, regular shops and directly to the Health
Care community. The share is listed on Nasdaq Stockholm.
Julian Aleksov
Tel: +46 18 50 54 40
E-mail: julian.aleksov@oasmia.com